GlassScriptPhysician profile
Joseph T Morandi
NPI 1245209642
$3,454.54
in general payments reported to CMS, 2019-2025
34 companies · $273 in 2025
The $273 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $884 · 2020: $508 · 2021: $581 · 2022: $243 · 2023: $261 · 2024: $705 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,192 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,191.98 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $641.39 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $609.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $433.75 | 2020-2025 | |
| Lilly USA, LLC | $269.63 | 2019-2025 | Zepbound, Mounjaro |
| Allergan, INC. | $204.34 | 2019-2020 | |
| Bausch Health US, LLC | $150.06 | 2019-2025 | Wellbutrin, Aplenzin |
| Merck Sharp & Dohme LLC | $129.21 | 2019-2022 | |
| Pfizer INC. | $110.44 | 2019-2025 | |
| Ibsa Pharma INC. | $104.80 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.62 | 2024 | Caplyta |
| Novartis Pharmaceuticals Corporation | $74.68 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $60.62 | 2023 | Quviviq |
| Kaleo, INC. | $55.09 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $50.79 | 2020-2022 | |
| Alk-Abello, INC | $42.71 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $41.87 | 2023 | Repatha, Otezla |
| Astellas Pharma US INC | $40.97 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $39.44 | 2019-2022 | |
| Lundbeck LLC | $33.85 | 2024 | Rexulti |
| Paratek Pharmaceuticals, INC. | $31.55 | 2024 | Nuzyra |
| Acadia Pharmaceuticals INC | $27.40 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.91 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $17.44 | 2024 | Horizant |
| Cleerly, INC. | $17.38 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Phathom Pharmaceuticals, INC. | $17.21 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $16.83 | 2024 | Eliquis |
| Althera Pharmaceuticals LLC | $16.23 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $14.69 | 2024 | Rexulti |
| Bardy Diagnostics, INC. | $14.00 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.60 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.40 | 2019 | |
| Exact Sciences Corporation | $13.24 | 2024 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $11.52 | 2019 | |
| Gilead Sciences, INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Morandi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.